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Abstract
Background: The ability to identify patients for hospice care results in better end-of-life care. To
develop a validated prognostic scale for 7-day survival prediction, a prospective observational
cohort study was made of patients with terminal cancer.
Methods: Patient data gathered within 24 hours of hospital admission included demographics,
clinical signs and symptoms and their severity, laboratory test results, and subsequent survival data.
Of 727 patients enrolled, data from 374 (training group) was used to develop a prognostic tool,
with the other 353 serving as the validation group.
Results: Five predictors identified by multivariate logistic regression analysis included patient's
cognitive status, edema, ECOG performance status, BUN and respiratory rate. A formula of the
predictor model based on those five predictors was constructed. When probability was >0.2, death
within 7 days was predicted in the training group and validation group, with sensitivity of 80.9% and
71.0%, specificity of 65.9% and 57.7%, positive predictive value of 42.6% and 26.8%, and negative
predictive value (NPV) of 91.7% and 90.1%, respectively.
Conclusion: This predictor model showed a relatively high sensitivity and NPV for predicting 7-
day survival among terminal cancer patients, and could increase patient satisfaction by improving
end-of-life care.
Background
In hospice palliative care, an important issue is the ability
to accurately predict the probability of survival of terminal
cancer patients with short-term survival. Patients, family
members, and providers may desire this information for
their plans and decisions about "pain and distress;" clini-
cians may want to improve their prognostic skills [1,2].
When death is near, goals and plans of management often
shift and a clinical pathway has been developed to guide
care [3]. For example, patients expected to live for 1-2
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weeks are incapable of oral fluid intake due to progressive
cachexia and show a performance status of more than 3
points in the Eastern Cooperative Oncology Group
(ECOG) scale. To improve general quality of life in these
patients, simple hydration at 1000-1500 mL/day (400-
600 kcal/day) is not recommended [4]. Prediction of
short-term survival is important in the palliative care unit
to improve quality of care at the end of life, in Taiwan as
elsewhere.
Previous studies have shown that the accuracy of various
prognostic scales is overoptimistic. A report of the meta-
analysis suggested that survival of patients is typically
30% shorter than predicted in terminally ill cancer
patients [5]. Another result from a systematic electronic
literature search suggested that Clinical Prediction of Sur-
vival (CPS) is more than twice as likely to be overoptimis-
tic versus overpessimistic, and to overestimate the length
of actual survival by a factor of between 3 and 5 in
advanced cancer patients [6]. Those scales are generated
according to clinical symptoms and signs, which can vary
considerably, although weakness and pain seem to be the
most prevalent symptoms [7]. In several major studies,
some laboratory parameters have been shown to be capa-
ble of providing additional prognostic information [8].
Nevertheless, a simple and accurate predictor for cancer
patients is yet to be developed.
Despite a consensus for the need for survival prediction in
patients with terminal cancer; both predictors selected
and model vary widely. For established prognostic scales,
accuracy varies from 0.61 to 0.82, decreasing with shorter
survival prediction. Reuben's predicted survival table
assesses terminal patients by six symptoms and signs:
Karnofsky Performance Status (KPS), dyspnea, anorexia,
dysphagia, xerostomia, and weight loss, with KPS the
most important factor. Clinicians can predict a patient
with the worst KPS score of surviving 16 days by 50% as
well as 72 days by 10% if the other five factors exist. Accu-
racy for this model was not calculated [9]. Bruera's Poor
Prognostic Indicator depends on three symptoms and
signs as prognostic factors: dysphagia, cognitive barriers,
and weight loss (refers to 10 kg weight loss within 6
months). Accuracy was calculated based on the PPV and
NPV. When terminal patients meet these three prognostic
factors, the anticipated survival time, within 4 weeks, is
74% accurate. The sensitivity of the model was 76%, spe-
cificity was 71%, PPV was 76%, NPV was 71%, [10].
Morita's Palliative Prognostic Index proposes five inde-
pendent prognostic factors: physical function status
(modified KPS), eating by mouth, edema, dyspnea, and
delirium. When scores are more than six, survival time is
less than three weeks with accuracy of 0.82. When scores
are more than four, survival time is less than six weeks
with accuracy of 0.77. Accuracy was calculated based on
PPV and NPV [11]. Maltoni's Palliative Prognostic Score
was developed from patient symptoms and signs, and
complete blood count. This scale consists of six prognostic
factors (e.g., dyspnea, anorexia, KPS, total white blood cell
count and lymphocyte percentage, and clinical prediction
of survival by experienced physicians). Maltoni found that
the scale was as accurate as prediction by an experienced
physician [12], with greatest accuracy from a combination
of subjective prognostic judgements and objective vali-
dated tools [13].
Most recently, Chow's predictive model [14], Stone's
prognostic scale [15], Chuang's prognostic score [16] and
Bozcuk's intrahospital cancer mortality risk model [17]
were developed to predict survival, and the latest three are
for short-term survival. Of these, Chow's predictive model
of the three-variable number of risk factors (NRF) -- non-
breast cancer, metastases other than bone and Karnofsky
performance score <6_0 -- is clinically simple and user-
friendly. For 3-month survival, this model estimates prob-
ability of patients with NFR ≤ 1, NFR = 2, NFR = 3 were
83%, 76%, and 44% respectively, in external validation
set. In this model, all subjects were attending a palliative
radiotherapy clinic. Stone's prognostic scale uses four var-
iables: primary lung cancer, secondary liver cancer, C-reac-
tive protein, and poor performance status (ECOG = 4) to
predict 14-day survival. Stone's prognostic scale would
have more value for identifying those patients not suitable
for hospice admission, due to high predictive value
(85%), and low positive predictive value (PPV) (39%). By
contrast, Kelly's model suggested C-reactive protein as the
simple prognostic indicator in patients with advanced
cancer [18].
Chuang et al. constructed a prognostic scale with units
including liver and lung metastasis, ECOG, weight loss,
edema, cognitive impairment, fatigue, and ascites. Accu-
racy was directly derived from PPV and NPV. When the
cutoff score was >6.0, PPV and NPV for patients with sur-
vival time < 1 week were 0.75 and 0.70 in the training set
(accuracy, 0.72). For the testing set, values were 0.43 and
0.76, respectively (accuracy, 0.66) [10]. Bozcuk's intrahos-
pital cancer mortality risk model predicted the probability
of terminal cancer patients dying within 8 days. The scale
was constructed based on predictors including ECOG
score, duration of disease, emergency admission, Hb
count and LDH level. Accuracy was expressed by ROC area
(AUC). In the retrospective cohort, this model had an
ROC area of 0.88 (P < 0.001, 95% CI: 0.84-0.92), whereas
in the prospective cohort, it yielded an ROC area of 0.82
(P < 0.001, 95% CI: 0.73-0.90) [17].
Research has indicated that the rate of survival of less than
7 days in patients in hospice wards is about 15% [19]. In
Taiwan, where patients with terminal cancer are referredBMC Public Health 2009, 9:365 http://www.biomedcentral.com/1471-2458/9/365
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to hospice for palliative care late in the course of their dis-
ease, the figure is approximately 30% [20,21]. In one Tai-
wanese study, only 3.5% of patients referred late in the
course of the disease to hospice care lived longer than 180
days [21]; in Italy, a prospective cohort study showed that
referral of cancer patients to palliative, end-of-life care
tends to occur late in the course of the disease [22].
In Taiwan, between 2000 and 2004, the rates of late refer-
rals for hospice care as a whole were 25.3%-28.9%, which
were lower than the national statistics from the United
State (35.1%), but higher than other published study
reports (15.6%-20%) [23]. Furthermore, evidence sug-
gests that late hospice referral increase the risk of a major
depressive disorder in the first year of bereavement [24].
When patients were enrolled in hospice for less than 7
days, the hospice team often did not have adequate time
to become familiar with patients and their home situa-
tion. The goal for comprehensive care (including the
patients' wish such as to die at home) might become
impossible to fulfill [25]. Part of the explanation for late
referral can be attributed to difficulties in establishing an
accurate prognosis [26].
In Taiwan, hospice care includes inpatient hospice care
and hospice home care. In Taiwan, in 2004, overall utili-
zation of hospice care is 15.4%, and hospice home care
only is 2.6%, inpatient hospice care only is 10.1%, and
both home care and inpatient care is 2.8%. Our study was
inpatient hospice care [23].
Palliative care seeks to fulfill the needs of patients at the
end of life. Ascertaining and carrying them out (e.g., the
desire to die at home) requires the ability to predict short
term survival. This study aimed to develop a validated
model for 7-day survival prediction for terminal cancer
patients to make more accurate prediction of short-term
survival in order to facilitate timely referrals to palliative




We conducted a prospective observational cohort study
for patients with terminal cancer. Of 727 terminal cancer
patients from a hospice ward admitted from November
2004 to June 2007 in the Buddhist Dalin Tzu Chi General
Hospital, the first 374 diagnosed with terminal cancer
were chosen as the training group by which we would
develop a prognostic measurement. The same measures
were tested on the next 353 patients, the validation group.
For the training group, number of admission during the
study period was 415 cases, of which 374 cases were
enrolled (91%). For the Validation group, the number of
admissions during the study period was 430 cases, of
which 353 cases were enrolled (82%). Overall percentage
of enrollment was 86%. Most cases not enrolled were due
to admission during a holiday or weekend.
Inclusion criteria were terminally ill cancer patients
admitted to the palliative care unit at our hospital who
were referred from other wards of the same hospital, from
other hospitals or from home. All patients enrolled met
with normative standards of hospice palliative enactment
in Taiwan. Excluded were patients referred to other hospi-
tals, since we could not accurately assess their complete
records. Patient recruitment and study design were
approved by the Institutional Review Board of Buddhist
Dalin Tzu Chi General Hospital (Nos. B09303011 and
B09502017). All patients gave their informed consent
before being entered into the study. For those uncon-
scious patients, we obtained proxy consent from relatives.
Data collection
Data on demographics, clinical symptoms and signs and
their severity, laboratory test results, and subsequent sur-
vival were collected by an experienced hospice team
(comprising physicians and registered nurses) within 24
hours of hospice admission. When verbal communication
with any patient was difficult due to the cognitive impair-
ment, interviewers assessed these patients' status with
their family caregiver. The proportion of unconscious
patient in training group was 4.8%. (cognitive impair-
ment = 3, 18/374 = 4.8%) and the proportion of uncon-
scious patient in validation group was 8.2% (cognitive
impairment = 3, 29/353 = 8.2%).
Almost all clinical symptoms and signs were collected
according to those identified in previous studies [27-29].
Eighteen symptoms and signs were assessed, including
pain, dyspnea, tiredness, heart rhythm (irregular versus
regular), poor appetite (<500 cc of milk or <2 bowls of
porridge by mouth or tube feeding within 24 hours of
admission), medication for insomnia, nausea, vomiting,
constipation, edema (scored as 0 = no; 1 = less than 1/2
finger breadth; 2 = 1/2 - 1 finger breadth; and 3 = >1 finger
breadth), ascites (scored as 0 = no; 1 = only by ultrasound;
2 = shifting dullness by physical examination; 3 = umbil-
ical protrusion), jaundice (scored as 0 = no; 1 = slightly
yellowish; 2 = remarkably yellow; and 3 = deeply yellow
or greenish), cognitive status (scored as 0 = clear; 1 = leth-
argy; 2 = confusion; 3 = comatose), performance status
score according to the ECOG (range: 1-4), fever (core tem-
perature ≥ 37.5°C), pressure sores, mean muscle power
(sum of muscle power of each extremity divided by four,
muscle powers graded using the Medical Research Coun-
cil (MRC) scale of 0-5: 5 = normal power, 4 = moderate
movement against resistance, 3 = movement against grav-
ity but not against resistance, 2 = movement with gravity
eliminated, 1 = flicker of movement, 0 = no movement),BMC Public Health 2009, 9:365 http://www.biomedcentral.com/1471-2458/9/365
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naso-gastric tube, and intervention tube placement (e.g.,
percutaneus nephrostomy (PCN), percutaneous transhe-
patic cholangio drainage (PTCD), pig tail for pleural effu-
sion or ascites drainage, jejunostomy tube and
percutaneous endoscopic gastrostomy tube). An addi-
tional 12 laboratory items were examined: complete
blood count (e.g., white blood cell (WBC) count (normal
range: male: 3.8-9.8*103/μL, female: 3.6-9.6*103/μL) and
differential percentages, hemoglobin (normal range:
male: 13-18 g/dL, female: 12-16 g/dL), and platelet (nor-
mal range: 120-320*103/μL); and biochemistry examina-
tion: blood urea nitrogen (BUN) (normal range: ≤20 mg/
dL), creatinine (normal range: ≤1.2 mg/dL), serum
glutamic oxaloacetic transaminase (SGOT) (normal
range: ≤38 IU/L), serum glutamic pyruvate transaminase
(SGPT) (normal range: ≤41 IU/L), total bilirubin (normal
range: ≤1.0 mg/dL), albumin (normal range: 3.4-4.8 g/
dL), corrected calcium (normal range: 2.1-2.55 mmol/L),
and blood sugar (normal range:70-110 mg/dL). Duration
of survival days, which was defined as the period (in days)
from the date of a hospice ward admitted to the date of
death, or the end of follow-up, were also recorded.
The research team extracted independent prognostic fac-
tors from the 375 patients in the training set to establish a
predictor model and then employed that predictor model
to test the 353 patients in the validation group. The end-
point consisted of factors associated with the patient's
expectation of dying within 7 days.
Data Analysis
Comparability between the 2 groups was tested using
Mann-Whitney-U test for skewed variables and Chi-
square test for categorical variables. Nonparametric varia-
bles were represented as median (inter-quartile range)
and categorical data were represented by number (n) and
percentage (%). The survival rates were calculated by the
Kaplan-Meier method and the differences between the
survival curves were examined by the log-rank test. Uni-
variate logistic regression analysis was performed to ana-
lyze the odds ratio of significant factors associated with
patients who expired within 7 days. Variables having a p
value < 0.05 in the univariate analysis were selected and
evaluated by multivariate logistic regression models. Fur-
thermore, a receiver operating characteristic (ROC) curve
was employed in the training group to obtain the area
under the curve (AUC), sensitivity, specificity, PPV and
negative predictive value (NPV). All statistic assessments
are two sided and evaluated at the 0.05 level of signifi-
cance. Statistic analyses were performed using SPSS 15.0
statistics software (SPSS Inc, Chicago, IL).
Results
The demographic characteristics of the training and vali-
dation groups are shown in Table 1. The training group
had a median age of 67 (inter-quartile range = 58, 75);
lung cancer was the most common diagnosis cancer
(20.6%), 51.1% received chemotherapy as the most fre-
quent type of treatment and the group was 61.0% male.
The validation group had the same median age of 67
(inter-quartile range = 58, 75); liver cancer was the most
common cancer diagnosis (20.1%), 53.8% received
chemotherapy as the most frequent type of treatment and
the group was 58.1% male. The groups were statistically
significantly different in frequency of diagnosis of diabe-
tes mellitus, incidence of head neck cancer, having radio-
therapy treatment, and level of creatinine and albumin (P
< 0.05). The survival rates were significantly different
between the training and validation groups. The median
survival dates were 17 and 22 days for the training and
validation groups, respectively (Figure 1). Table 2 shows
the prevalence of significant clinical signs by severity. The
training and validation groups differed significantly in
cognitive status, ECOG score, and ascites (P < 0.05).
Table 3 presents the results of univariate and multivariate
analysis of determinants of whether a patient would die
within the next 7 days. The univariate logistic regression
model indicated the following prognostic factors: diagno-
sis of liver cancer, cognitive status, edema, jaundice,
ECOG score, ascites, WBC, platelet, BUN, creatinine,
SGOP, SGPT, albumin level and respiratory rate (P  <
0.05). Variables having a P value < 0.05 in the univariate
analysis were selected and evaluated by multivariate logis-
tic regression models. Multivariate logistic regression indi-
cated that cognitive status (1 to 3 vs. 0, OR: 2.29, P =
0.014), edema (1 to 3 vs. 0, OR: 1.94, P = 0.038), ECOG
score (3 and 4 vs. 1 and 2, OR: 3.45, P = 0.001), BUN and
respiratory rate (on a linear scale, OR: 1.12, P = 0.004)
were significantly associated with the likelihood of
patients dying within 7 days.
From this information we used variables identified by
multivariate logistic regression to construct the following
formula for the predictor model:
log [probability of dying within 7 days/(1- probability
of dying within 7 days)] = [- 5.37 + 0.864* cognitive
status (1 if cognitive = 0, 0 if otherwise) + 0.782*
edema (1 if edema = 0, 0 if otherwise) + 1.208* ECOG
(1 if ECOG = 1 and 2, 0 if otherwise) + 0.022*BUN +
0.104*respiratory rate].
Figure 2 shows the ROC curve of the training group from
which the cut-off point was chosen. The area under the
curve (AUC) was 0.81 (P < 0.001, 95% CI: 0.76 to 0.86).
The researchers decided to designate the cut-off point as
probability of 0.2 in both training and validation groups.
Table 4 presents the sensitivity and specificity of the
model. When probability was >0.2, 7 days' survival wasBMC Public Health 2009, 9:365 http://www.biomedcentral.com/1471-2458/9/365
Page 5 of 9
(page number not for citation purposes)
predicted for terminal patients in the training group and
the validation group, with sensitivity of 80.9% and
71.0%, respectively; specificity of 65.9% and 57.7%,
respectively; PPV of 42.6% and 26.8%, respectively; NPV
of 91.7% and 90.1% (Table 4).
Using this cut-off point, we observed 80.9% sensitivity
and 65.9% specificity to predict whether the terminal can-
cer patients died within 7 days. The PPV for predicting
death within 7 days was 42.6%, but the NPV for not dying
within 7 days was 91.7%, suggesting that the model may
be more reliable for predicting the 7-day survival. The
same model was subsequently validated in a separated
group of terminal patients. We observed 71.0% sensitivity
and 57.7% specificity to predict the patients who died
within 7 days. The PPV for predicting death within 7 days
was 26.8%, and the NPV for not dying within 7 days was
90.1%. All these parameters of validation group were
lower than those of training group, but sensitivity was still
over 70% and the model also showed more reliability for
predicting 7-day survival than death within 7 days.
Discussion
The present study proposes a predictor model to estimate
probability of 7-day survival for patients in terminal-stage
cancer. The five predictors identified by multivariate logis-
tic regression analysis were patient's cognitive status,
edema, ECOG performance status, BUN and respiratory
rate. A formula of the predictor model including these five
predictors was developed and tested in both the training
and validation groups. The cut-off point of probability of
0.2 was chosen based on the ROC curve of the training
group. In our study, the area under the curve (AUC) was
0.81 (P < 0.001, 95% CI: 0.76 to 0.86). When the proba-
bility was >0.2, terminal patients died within 7 days was
predicted in the training group and the validation group,
Table 1: Patient characteristics in the training and validate sets.
Training (n = 374) Validation (n = 353) P-value
Age (years) 67 (54, 75) 67 (58, 75) 0.318
Gender 0.428
Male 228 (61.0%) 205 (58.1%)
Female 146 (39.0%) 148 (41.9%)
Diabetes mellitus 92 (24.6%) 120 (34.2%) 0.005*
Hypertension 151 (40.4%) 148 (41.9%) 0.671
Diagnosis
Lung cancer 77 (20.6%) 58 (16.4%) 0.150
Liver cancer 74 (19.8%) 71 (20.1%) 0.912
Colon cancer 44 (11.8%) 42 (11.9%) 0.956
Stomach cancer 18 (4.8%) 25 (7.1%) 0.195
Head Neck cancer 41 (11.0%) 58 (16.4%) 0.032*
Pancreas cancer 16 (4.3%) 14 (4.0%) 0.833
Male GU cancer 16 (4.3%) 11 (3.1%) 0.408
Female GU cancer 27 (7.2%) 22 (6.2%) 0.596
Breast cancer 16 (4.3%) 9 (2.5%) 0.201
Esophagus cancer 11 (2.9%) 12 (3.4%) 0.833
Unknown and others 46 (12.3%) 50 (14.2%) 0.458
Treatment
Operation 154 (41.2%) 165 (46.9%) 0.122
Chemotherapy 191 (51.1%) 190 (53.8%) 0.457
Radiotherapy 116 (31.0%) 143 (40.5%) 0.008*
Laboratory Parameters
WBC (*1000/cumm) 10.01 (7.05, 15.19) 10.41 (7.34, 14.93)† 0.824
Hemoglobin (g/dl) 10.3 (9.1, 11.7) 10.6 (8.9, 11.9)† 0.340
Platelet (*1000/cumm) 210 (128, 312) 222 (138, 331)† 0.309
Glucose (mg/dl) 117 (99, 147) 118 (97, 156)† 0.941
BUN (mg/dl) 21 (15, 32) 19 (12, 32)† 0.067
Creatinine (mg/dl) 0.9 (0.7, 1.4) 0.7 (0.5, 1.1)† <0.001*
SGOT (IU/L) 34 (20, 70) 35 (22, 81)† 0.335
SGPT (IU/L) 23 (14, 46) 26 (15, 47)† 0.382
Albumin (g/dl) 3.1 (2.7, 3.4) 2.8 (2.4, 3.2)† <0.001*
* Statistically significant.
BUN = blood urea nitrogen; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic pyruvate transaminase.
† Missing values were observed in this variable in the validation set.BMC Public Health 2009, 9:365 http://www.biomedcentral.com/1471-2458/9/365
Page 6 of 9
(page number not for citation purposes)
with sensitivity of 80.9% and 71.0%, specificity of 65.9%
and 57.7%, PPV of 42.6% and 26.8%, and NPV of 91.7%
and 90.1%, respectively.
The predictors in our model agreed with other most recent
models. ECOG performance status was a strong predictor
(odd ratio = 6.13 in univariate logistic model, and 3.45 in
multivariate analysis), as in Chuang's and Bozcuk's
reports [16,17]. Cognitive score, another strong predictor
(odd ratio = 3.62 in univariate logistic model, and 2.29 in
multivariate analysis), was also identified by Bruera and
Chuang [10,16]. Like us, Morita and Chuang identified
edema as a significant predictor for length of survival
among terminal cancer patients [11,16]. Accuracy of our
study, expressed by ROC area (AUC), was comparable to
that of Bozcuk [17].
The uniqueness of our model was the inclusion of blood
urea nitrogen (BUN), and respiratory rate, one of the basic
vital signs, in the formula. The study shows that BUN is
Table 2: Prevalence of significant clinical signs by severity.
Clinical signs Training(n = 374) Validation(n = 353) P-value
Cognitive 0.014*
0 273 (73.0%) 228 (64.6%)
1 to 3 101 (27.0%) 125 (35.4%)
Edema 0.508
0 190 (50.8%) 188 (53.3%)
1 to 3 184 (49.2%) 165 (46.7%)
Jaundice 0.747
0 264 (70.6%) 253 (71.7%)
1 to 3 110 (29.4%) 100 (28.3%)
ECOG score <0.001*
1 and 2 167 (44.7%) 26 (7.4%)
3 and 4 207 (55.3%) 327 (92.6%)
Ascites <0.001*
0 218 (58.3%) 265 (75.1%)
1 to 3 156 (41.7%) 88 (24.9%)
* Statistically significant.
Survival curve of the training and validation groups Figure 1
Survival curve of the training and validation groups.BMC Public Health 2009, 9:365 http://www.biomedcentral.com/1471-2458/9/365
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more significant for survival than creatinine. Elevation of
BUN is termed azotemia. Terminal azotemia means the
state of terminal dehydration, gastrointestinal bleeding,
and others of patients [30]. Only Chung attempted to pre-
dict survival within the one week window. We included
fewer predictors than Chuang [16], whose eight character-
istics include liver and lung metastases. Borzuk showed a
similar area under the curve to ours, but only tested likeli-
hood of dying in the hospital, not death within seven days
[17]. We also found that the higher the respiratory rate,
the greater the possibility of survival of less than one
week.
This scale is an important improvement over previous
methods. First, every terminally ill cancer patient receives
the probability of 7-day survival within 24 hours of
admission by our prognostic scale. The reader can use the
method indicated in the supplementary information to
calculate the probability. Second, we have identified a lab-
oratory factor (BUN) and patient vital sign (respiratory
rate) as additional prognostic parameters. Thirdly, this
prognostic scale shows relatively high sensitivity (80.9%)
and NPV (91.7%) for predicting 7-day survival among ter-
minal cancer patients. This means that our prognostic
scale has more value for identifying those patients not late
referral for hospice care than for positively identifying
those patients within 7 days of death.
Correct survival estimations in terminally ill cancer
patients helps prevent inappropriate therapies, avoid
actions that could worsen the patient's quality of life, and
Table 3: Determinants of patients who died within 7 days in the training set (n = 374).
Univariate analysis Multivariate analysis
O.R. 95%CI P-value O.R. 95%CI P-value
Age (years) 1.01 (0.99, 1.03) 0.272
Gender (male vs. female) 1.53 (0.92, 2.54) 0.099
Diabetes mellitus (yes vs. no) 0.98 (0.52, 1.85) 0.953
Hypertension (yes vs. no) 0.68 (0.36, 1.26) 0.215
Cancer diagnosis
Lung cancer (yes vs. no) 1.27 (0.72, 2.25) 0.411
Liver cancer (yes vs. no) 2.22 (1.28, 3.86) 0.004* 1.63 (0.76, 3.50) 0.212
HN** cancer (yes vs. no) 0.63 (0.27, 1.48) 0.292
Treatment
Operation (yes vs. no) 0.66 (0.40, 1.09) 0.107
Chemotherapy (yes vs. no) 1.27 (0.78, 2.05) 0.337
Radiotherapy (yes vs. no) 0.87 (0.51, 1.47) 0.590
Clinical signs
Cognitive (1 to 3 vs. 0) 3.62 (2.18, 6.02) <0.001* 2.29 (1.18, 4.43) 0.014*
Edema (1 to 3 vs. 0) 2.32 (1.42, 3.82) 0.001* 1.94 (1.04, 3.62) 0.038*
Jaundice (1 to 3 vs. 0) 2.23 (1.35, 3.67) 0.002* 1.00 (0.47, 2.15) 0.999
ECOG score (3, 4 vs. 1, 2) 6.13 (3.31, 11.37) <0.001* 3.45 (1.65, 7.19) 0.001*
Ascites (1 to 3 vs. 0) 1.94 (1.20, 3.15) 0.007* 1.01 (0.49, 2.11) 0.975
Laboratory Parameters
WBC (*1000/cumm) 1.03 (1.01, 1.05) 0.012* 1.02 (1.00, 1.04) 0.095
Hemoglobin (g/dl) 1.05 (0.93, 1.17) 0.445
Platelet (*1000/cumm) 1.00 (1.00, 1.01) 0.031* 1.00 (1.00, 1.01) 0.145
Glucose (mg/dl) 1.00 (0.99, 1.00) 0.350
BUN (mg/dl) 1.03 (1.02, 1.04) <0.001* 1.02 (1.00, 1.03) 0.017
Creatinine (mg/dl) 1.46 (1.18 1.80) <0.001* 1.00 (0.71, 1.41) 0.993
SGOT (IU/L) 1.00 (1.00, 1.01) 0.002* 1.00 (1.00, 1.01) 0.155
SGPT (IU/L) 1.01 (1.00, 1.01) 0.016* 1.00 (0.99, 1.01) 0.806
Albumin (g/dl) 0.56 (0.35 0.90) 0.016* 0.88 (0.50, 1.56) 0.666
Respiratory rate 1.12 (1.01, 1.19) <0.001* 1.12 (1.04, 1.20) 0.004*
* Statistically significant.
** HN: Head Neck.
Table 4: Sensitivity and specificity of cut-off prognostic survival 
scale for patients dying within seven days in both training and 
testing samples.





PPV: Positive Predictive Value; NPV: Negative Predictive Value
* Missing data in the validation group: 1 in data for BUN and 3 in data 
for Respiration rate.BMC Public Health 2009, 9:365 http://www.biomedcentral.com/1471-2458/9/365
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allows for support for patients and families by timely
referred to hospice care. Knowing the approach of one's
death can make for better decision-making and quality of
life. Using Kellehear's model of spiritual needs, Leung et
al. found that awareness of terminal illness was associated
with well-being, even at the end of life [31]. Accurate pre-
diction of survival is vital in planning effective palliative
care and appropriately adjusting some medications [11].
Timely referral was associated with greater satisfaction in
both patients and their family members [32].
Our study had some limitations. First, the degree of hos-
pice and palliative care varies around the world, so includ-
ing a representative population at similar and specific
points during the course of their terminal illness is diffi-
cult [33]. Certain variables including survival and some
clinical signs by severity (e.g., cognitive, ECOG score,
ascites) were statistically different in both groups. How-
ever, this limitation shows that the participants of both
groups were selected sequentially without bias, as in other
studies [16,17]. Second, some data may inevitably intro-
duce bias. For example, the data on weight lost were based
on information provided by patients' relatives when the
patient could not accurately recall body weight three
months prior. In addition, a limited number of patients
(8.2%) were assessed by family caregivers rather than by
patients due to the cognitive impairment, which may have
introduced some bias. Finally, a hospital-based study may
not fully apply to community-based patients. In the
present study, the number of patients meeting the inclu-
sion criteria was limited in a community hospital setting.
This could be an issue for further study.
In addition, the study has certain strengths. The NPV of
our prognostic scale is 91.7%, and 90.1%, respectively, in
the training and validation groups. This means that our
prognostic scale would have more value for identifying
those patients not late referral to hospice care than for pos-
itively identifying those patients with 7 days to death.
Also, it provides a calculation (by R syntax or excel) for
determining probability of survival within 7 days.
Conclusion
This prognostic scale, including patient's cognitive status,
edema, performance status, BUN and respiratory rate,
showed a relatively high sensitivity and NPV for predict-
ing 7-day survival among terminal cancer patients. We
believe the proposed scale could be useful for predicting
survival 7-day for terminal cancer patients, in addition,
not late referral to hospice care.
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